Impel NeuroPharma to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021
08/09/2021 - 04:01 PM
SEATTLE, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced it will host a live webcast on Monday, August 16, 2021 at 8:30 a.m. ET to report its second quarter 2021 financial results and provide a business update.
A live webcast of the event will be available on the Investors section of the Impel NeuroPharma website at https://investors.impelnp.com/ . A replay of the webcast and accompanying slides will be available on the Impel NeuroPharma website following the event.
About Impel NeuroPharma
Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.
Investor Relations : Christina Tartaglia Stern Investor Relations Phone: (1) 212-362-1200 Email: christina.tartaglia@sternir.com
Media Relations : Melyssa Weible Elixir Health Public Relations Phone: (1) 201-723-5805 Email: mweible@elixirhealthpr.com
Impel Pharmaceuticals Inc
IMPL Rankings
N/A Ranked by Stock Gains
IMPL Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Country
US
City
Seattle
About IMPL
impel neuropharma, inc., is a privately-held, seattle-based company devoted to creating life-changing, innovative therapies for central nervous system (cns) diseases. impel's products are based on a novel nasal drug delivery platform, the pod™ device, that administers drug to the upper nasal cavity in a consistent and predictable manner. impel neuropharma is currently investigating inp104 (pod™ dhe) for acute migraine headache, inp103 (pod™ levodopa) for parkinson's disease, inp105 (pod™ olanzapine) for agitation in schizophrenia and bipolar disorders as well as inp102 (pod™ insulin) for alzheimer's disease in an nih funded trial. impel neuropharma's proprietary pod™ device enables small and large molecule drugs to be administered using a cost-effective, disposable, non-invasive intranasal drug delivery device. to learn more about impel neuropharma, please visit our website at http://impelnp.com.